印度首次登革热疫苗已接近完成第3阶段试验, India's first dengue vaccine nears completion of Phase-3 trials amid rising public health concerns.

印度第一种登革热疫苗“登革热疫苗”“登革热疫苗”已接近第3阶段临床试验的尾声,目标是到10月在20个中心登记10 500名参加者。 India's first dengue vaccine, DengiAll, is nearing the end of its Phase-3 clinical trial, aiming to enroll 10,500 participants by October across 20 centers. 该试验由国际公路货运理事会和Panacea Biotec共同牵头,评价疫苗的安全性和功效。 The trial, co-led by the ICMR and Panacea Biotec, evaluates the vaccine's safety and efficacy. 截至3月,印度报告有12 043例登革热病例,疫苗的研制是解决这一公共卫生问题的一个重要步骤。 With around 12,043 dengue cases reported in India by March, the vaccine's development is a significant step in addressing this public health concern.